Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533857 | 1.00 | MAPT (0.48) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL16796582 | 0.78 | TRPA1 (0.52) | MAPTLMNACA2CA1CA4 | |
| SCHEMBL276965 | 0.76 | TRIM24 (0.52) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL31000832 | 0.76 | TRIM24 (0.52) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL2104023 | 0.76 | KDM4E (0.51) | MAPTLMNAKDM4EMAPK1 | |
| SCHEMBL2104022 | 0.76 | KDM4E (0.51) | MAPTLMNAKDM4EMAPK1 | |
| SCHEMBL2353413 | 0.74 | TRIM24 (0.47) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL4924447 | 0.73 | MAPT (0.55) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL15271482 | 0.73 | MAPT (0.55) | MAPTLMNATRIM24TRIM33NFKB1 | |
| SCHEMBL28830141 | 0.73 | TRIM24 (0.56) | MAPTLMNATRIM24TRIM33NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107002293-B | Sequencing by synthesis using pulsed readout optics | 艾比斯生物科学公司 | 2020-12-08 | — | — | CN | claimed |
| US-20200123605-A1 | SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS | IBIS BIOSCIENCES, INC. | 2020-04-23 | — | — | US | claimed |
| EP-3194643-B1 | SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS | IBIS BIOSCIENCES INC (US) | 2020-02-19 | — | — | EP | claimed |
| US-10550428-B2 | Sequencing by synthesis using pulse read optics | IBIS BIOSCIENCES, INC. (US) | 2020-02-04 | — | — | US | claimed |
| EP-3221328-A1 | PHOTOBLOCKED PROBES AND METHODS FOR SEQUENTIAL DETECTION OF NUCLEIC ACIDS | Roche Diagnostics GmbH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-20170247755-A1 | SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS | IBIS BIOSCIENCES, INC. | 2017-08-31 | — | — | US | claimed |
| US-9745618-B2 | Photoblocked probes and methods for sequential detection of nucleic acids | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2017-08-29 | — | — | US | claimed |
| EP-3194643-A1 | SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS | Ibis Biosciences, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016079078-A1 | PHOTOBLOCKED PROBES AND METHODS FOR SEQUENTIAL DETECTION OF NUCLEIC ACIDS | ROCHE DIAGNOSTICS GMBH (DE) | 2016-05-26 | — | — | WO | claimed |
| US-20160138092-A1 | PHOTOBLOCKED PROBES AND METHODS FOR SEQUENTIAL DETECTION OF NUCLEIC ACIDS | ROCHE MOLECULAR SYSTEMS, INC. | 2016-05-19 | — | — | US | claimed |
| US-20060194258-A1 | Polypeptide array synthesis | AFFYMETRIX, INC. (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006064505-A2 | A SINGLE-STEP PLATFORM FOR ON-CHIP INTEGRATION OF BIO-MOLECULES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-06-22 | — | — | WO | claimed |
| US-6747143-B2 | PREPARATION OF SEQUENCES ON SUBSTRATE; OBTAIN SUBSTRATE, DEPOSIT ON PLATE SURFACE, INCUBATE WITH ACTIVATOR, REMOVE PROTECTIVE GROUPS, RECOVER BIOPOLYMER | AFFYMETRIX, INC. | 2004-06-08 | — | — | US | claimed |
| US-6660234-B2 | Generation of preferential nucleotide sequences on preferential substrate; obtain substrate, expose to activator, remove terminal groups, recover biopolymer | AFFYMETRIX, INC. | 2003-12-09 | — | — | US | claimed |
| US-5510270-A | GENERATING PATTERN OF LIGHT AND DARK AREAS BY SELECTIVELY IRRADIATING SURFACE AREAS; DEPROTECTING; CONTACTING WITH RECEPTOR TO IDENTIFY OLIGONUCLEOTIDE SHOWING COMPLEMENTARITY TO RECEPTOR | AFFYMAX TECHNOLOGIES N.V. | 1996-04-23 | — | — | US | claimed |
| US-5424186-A | Biosynthesis of oligonucleotides on solid substrate by irradiation of predefined segments to remove blocking agents; then coupling with nucleotide | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-06-13 | — | — | US | claimed |
| US-5412087-A | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-05-02 | — | — | US | claimed |
| EP-0476014-B1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECH NV (AN) | 1994-08-31 | — | — | EP | claimed |
| WO-1993022680-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF OLIGONUCLEOTIDES AND OTHER BIOLOGICAL POLYMERS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-11-11 | — | — | WO | claimed |
| US-5143854-A | LARGE SCALE PHOTOLITHOGRAPHIC SOLID PHASE SYNTHESIS OF POLYPEPTIDES AND RECEPTOR BINDING SCREENING THEREOF | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-09-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194258-A1 | Polypeptide array synthesis | MRPL21, NGLY1, PSAP | MAPT 2780/4885LMNA 3832/4885TRIM24 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.